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B cells infected by Epstein-Barr virus (EBV), a trans-
forming virus endemic in humans, are rapidly cleared
by the immune system, but some cells harboring the
virus persist for life. Under conditions of immunosup-
pression, EBV can spread from these cells and cause
life-threatening pathologies.We have generatedmice
expressing the transforming EBV latent membrane
protein 1 (LMP1), mimicking a constitutively active
CD40 coreceptor, specifically in B cells. Like human
EBV-infected cells, LMP1+ B cells were efficiently
eliminated by T cells, and breaking immune surveil-
lance resulted in rapid, fatal lymphoproliferation and
lymphomagenesis. The lymphoma cells expressed
ligands for a natural killer (NK) cell receptor, NKG2D,
andcouldbe targetedbyanNKG2D-Fc fusionprotein.
These experiments indicate a central role for LMP1 in
the surveillance and transformation of EBV-infectedB
cells in vivo, establish a preclinical model for B cell
lymphomagenesis in immunosuppressed patients,
and validate a new therapeutic approach.
INTRODUCTION
EBV is a g-herpes virus infecting and potentially transforming
human B-lymphocytes and establishing a life-long latent infec-tion in more than 90% of human beings. Because EBV-infected
B cells are rapidly eliminated by the immune system, EBV infec-
tion in childhood causes no or only mild symptoms, and primary
infection occurring in young adults can lead to a self-limiting lym-
phoproliferative disorder known as infectious mononucleosis
(Kutok and Wang, 2006). T cells play a main role in this immune
surveillance mechanism, but NK cells also participate (Hislop
et al., 2007; Orange, 2006). In infected individuals, EBV acquires
a ‘‘dormant’’ state in a minute fraction of B cells and persists for
life. Under conditions of immunosuppression, the virus can
spread from these few cells, resulting in explosive expansion
of infected B cells and their malignant transformation, as seen
in pathologies such as posttransplant lymphoproliferative
disorder (PTLD) and AIDS-associated B cell lymphoma (Kutok
and Wang, 2006). EBV is also associated with other B cell
lymphomas, including Hodgkin’s disease (HD) and Burkitt
lymphoma (BL) (Kutok and Wang, 2006), although the strategies
used by the transformed cells in these diseases to evade
immune surveillance are still elusive. A likely clue to this problem
lies in the various states of latency, which EBV can assume,
ranging from a highly restricted pattern of viral gene expression
in BL (latency I) to the expression of just a few EBV genes in
HD (latency II) and that of all latent genes in PTLD and AIDS-
associated B cell lymphoma (latency III) (Capello et al., 2003;
Ku¨ppers, 2003).
The EBV-encoded proteins LMP1 and LMP2A share functions
with receptors on normal B cells. LMP2A mimics a constitutively
active B cell receptor (BCR), which it can replace in B cell devel-
opment (Caldwell et al., 1998; Casola et al., 2004). LMP1 isCell 148, 739–751, February 17, 2012 ª2012 Elsevier Inc. 739
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Figure 1. Expression of Transgenic LMP1 Promotes B Cell Growth
In Vitro
(A) Targeting the conditional LMP1 allele into the Rosa26 locus. TV, targeting
vector; SA, splice acceptor.
(B) Immunoblotting of LMP1 in CD43-depleted splenic B cells from LMP1flSTOP
mice at the indicated time points following TAT-Cre treatment.
(C)ProliferationofTAT-Cre-treatedsplenicBcells fromLMP1flSTOPandwild-type
(WT) mice in culture. Data represent means of four parallel measurements ± SD.
(D) FACS analysis of cell size (left) and Fas expression (right) of such cells
2 days after TAT-Cre treatment.
Data in (C) and (D) are representative of two independent experiments.a functional homolog of constitutively active CD40, the major
costimulatory receptor on B cells (Thorley-Lawson, 2001).
LMP1 signals through tumor necrosis factor receptor (TNFR)-
associated factors (TRAFs) or TNFR-associated death domain
proteins (TRADD) to activate c-Jun N-terminal kinase (JNK),
extracellular signal-regulated kinase (ERK), p38, and canonical
and noncanonical nuclear factor-kB (NF-kB), promoting cell
growth and survival (Soni et al., 2007).
LMP1 expression is essential for the transformation of human
B cells by EBV (Kaye et al., 1993) and can by itself induce onco-
genic transformation of rodent fibroblasts (Wang et al., 1985). It
has been reported that LMP1-positive B cell lymphomas sporad-
ically develop in aged LMP1 transgenic mice. In these animals,
LMP1 expression was barely detectable at young age, a
phenomenon that is not yet understood (Kulwichit et al., 1998).
Here, we describe a mouse model of conditional LMP1
expression that can be used to study EBV-induced immune
surveillance and lymphomagenesis. This system also allowed
us to validate a new therapeutic approach, potentially targeting
EBV-driven malignancies in immunosuppressed patients.
RESULTS
LMP1 Promotes B Cell Growth In Vitro
To model EBV-associated B cell transformation, we generated
a Rosa26 allele allowing expression of LMP1 through excision
of a transcriptional/translational STOP cassette via Cre/loxP-
mediated recombination (LMP1flSTOP; Figure 1A). B cells isolated
from LMP1flSTOPmice expressed LMP1 following treatment with
TAT-Cre (Peitz et al., 2002) (Figure 1B) and proliferated in cell
culture, whereas TAT-Cre-treated wild-type (WT) B cells died
over time (Figure 1C). The induction of LMP1 was accompanied740 Cell 148, 739–751, February 17, 2012 ª2012 Elsevier Inc.by an increase in cell size and the upregulation of CD95/Fas, as
expected from earlier work (Le Clorennec et al., 2006; Uchida
et al., 1999) (Figure 1D). We subsequently used Fas as a reporter
for LMP1 expression in B cells.
Elimination of LMP1+ B Cells and Activation of T Cells
In Vivo
LMP1flSTOP mice were crossed to CD19-cre mice to induce
LMP1 expression in B cells from the pro/pre-B cell stage (Rickert
et al., 1995). Unexpectedly, the B cell compartment in the spleen
of adult CD19-cre;LMP1flSTOP mice was significantly reduced
compared toCD19-cre controls (Figure 2A and Figure S1A avail-
able online). The remaining B cells in the mutant mice had
escaped deletion of the STOP cassette (Figure S1B). No Fas-
expressing B cells were detected in the spleen (data not shown),
although a small fraction of CD19+Fas+ B cells (LMP1+ B cells)
were seen in the bone marrow (BM; Figure 2B). B cell develop-
ment in the BM of the mutant mice was disrupted, with an
increase of pro-B and decrease of pre-B immature and mature
B cells (Figures S1C–S1E). Because LMP1+ B cells survived
and proliferated in cell culture (Figure 1C), their counterselection
in vivo is unlikely a consequence of LMP1 toxicity. Considering
that EBV-infected human B cells are cleared by the host immune
system, we sought for a similar immune surveillance mechanism
in the mutant mice. Indeed, we detected increased populations
of activated CD4+ and CD8+ T cells in the BM of the mutants
(Figures 2C, 2D, and S1F). In addition, on day 8 after birth, we
found a significant population of CD19+Fas+ B cells in their
spleen (Figure 2E). The dynamics of CD19+Fas+ B cells and acti-
vated CD4+ and CD8+ T cells in the mutant mice between day 3
and 8 after birth suggest that a T cell immune response is
induced within this time period (Figures S2A–S2C).
Disruption of Immune Surveillance Leads to Rapid, Fatal
Expansion of LMP1+ B Cell Blasts in the Mutant Mice
To assess whether activated T cells are responsible for the elim-
ination of LMP1+ B cells, we injected a cocktail of depleting anti-
bodies (Abs) containing anti-CD4, -CD8, and -Thy1 into adult
CD19-cre;LMP1flSTOP and CD19-cre control animals at 3–4 day
intervals. At 2 weeks after the initiation of this treatment, the
majority of the mutant mice, but not the controls, became termi-
nally ill, presenting with splenomegaly due to marked expansion
of LMP1+ B cells (CD19+Fas+; Figures 3A and 3B). These cells
were largely confined to peripheral lymphoid organs and the
BM (Figure S3A), although infiltrations into the liver and rarely
into lung and kidney were occasionally seen (data not shown).
No outgrowth of LMP1+ B cells was seen in mutant mice treated
with anti-CD4, -CD8, or -Thy1 alone or a combination of anti-
CD4 and -CD8 (Figure S3A and data not shown). The latter
depleted TCRab T cells as efficiently as the combination of
anti-CD4, -CD8, and -Thy1 (data not shown), but the anti-Thy1
antibody might deplete TCRgd T cells, activated NK, and natural
killer T (NKT) cells in addition. Outgrowth of LMP1+ B cells was
also not seen upon treatment of the animals with anti-TNF-a
and/or anti-IFN-g blocking antibodies (data not shown; see
Extended Experimental Procedures for experimental details),
although both of these cytokines have been implicated in anti-
tumor immunity (Balkwill, 2009; Blankenstein and Qin, 2003;
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Figure 2. Elimination of LMP1+ B Cells and
Activation of T Cells in CD19-cre;LMP1flSTOP
Mice
(A and B) Representative FACS analysis of spleen
and BM cells from 6- to 12-week-old CD19-cre
and CD19-cre;LMP1flSTOP mice, respectively.
(C) Representative FACS analysis of T cells and
their activation status (CD69 expression) in the BM
of these mice. Boxed, percentage within lympho-
cyte gate.
(D) Numbers of CD4+TCRb+ and CD8+TCRb+
T cells in the BM of these mice. Bars show the
respective mean values.
(E) Representative FACS analysis of spleen cells
from CD19-cre and CD19-cre;LMP1flSTOP mice on
day 8 after birth. CD19+Fas+ indicates LMP1+
B cells.
See also Figure S1 and Figure S2.Ikeda et al., 2002; Koebel et al., 2007). The activated T cells in the
bone marrow of CD19-cre;LMP1flSTOP mice contained normal
proportions of cells expressing IFN-g, TNF-a, IL-4, and IL-17,
except for a 2-fold increase of the former in the CD8+ compart-
ment (Figure S3B). The LMP1+ cells were also not eliminated
solely because of Fas expression, as breedingCD19-cre;LMP1fl-
STOP mice on a Fas-deficient background (lpr/lpr) did not lead to
rescue of LMP1-expressing B cells (data not shown).
The Fas+ B cells arising in antibody-treated CD19-cre;
LMP1flSTOP mice resembled activated B cell blasts (CD19+,
B220low, Fas+, CD69+, CD5+, surface IgMlow, intracellular IgMhi,
CD138; Figure 3C and data not shown). They had deleted the
STOP cassette and expressed LMP1 (Figure 3D and data not
shown) as well as high levels of activation-induced cytidine
deaminase (AID) transcripts and protein (Figures 3E and 3F),
likely due to LMP1 signaling (He et al., 2003). Compared to WT
B cells and consistent with the signaling properties of LMP1
(Soni et al., 2007), the LMP1+ B cells exhibited higher levels of
p52 and lower levels of IkBa, indicating activation of the alterna-
tive and canonical NF-kB pathways. They also displayed higher
levels of phospho-ERK and phospho-JNK (p46), but not phos-
pho-p38 (Figure S3C). Approximately 5% of the cells were in
the S or G2 phase of the cell cycle, in contrast to < 1% of control
B cells (Figure S3D).
T Cell Control of LMP1+ B Cells
To unambiguously identify T cells as central players in the
surveillance of LMP1+ B cells, we crossed CD19-cre;LMP1flSTOP
to TCRb/;TCRd/mice. At 8–11 weeks of age, no CD19+Fas+
B cells were detectable in the spleens of CD19-cre;LMP1flSTOP
mice on a TCRb+/–;TCRd+/– or TCRb+/–;TCRd/ background,Cell 148, 739–751,whereas some such cells were present
on the TCRb/;TCRd+/– and substantial
numbers on the TCRb/;TCRd/ back-
ground (Figures 4A and 4B). Thus, TCRab
T cells are major effectors in controlling
LMP1+ B cells, but TCRgd T cells, which
are indeed expanded in the absence of
TCRab T cells (Figure 4C), also con-tribute. Further supporting this, essentially all of the CD19-
cre;LMP1flSTOP mice on a TCRb/;TCRd/ background died
over a period of 6–12 weeks. TCRgd T cells provided some
protection, and in the presence of TCRab T cells, the animals
readily survived the 24 week period of observation (Figure 4D).
LMP1+ Tumors Arise in T Cell-Ablated Mice
When terminally ill T cell-deficient CD19-cre;LMP1flSTOP mice
(Figure 4D) were examined for the cause of death, they all pre-
sented with splenomegaly and, occasionally, hepatomegaly.
Most of these mice developed tumors histologically resembling
diffuse large B cell lymphomas (DLBCL; six of nine cases),
whereas plasmacytic tumors were seen in the others (three of
nine cases) (Figure 5A). Immunohistochemically, all tumors
analyzed were positive for interferon regulatory factor 4 (IRF4;
five of five cases; Figure 5B and Table S1), a target of the
NF-kB pathway (Saito et al., 2007). Indeed, NF-kB activity in
tumor cells was comparable to the signals detected in control
B cells upon overnight CD40 stimulation, activating predomi-
nantly the alternative pathway (Figure S4A). Analysis of immuno-
globulin heavy-chain (IgH) gene rearrangements by Southern
blotting indicated that mice dying before 8 weeks of age dis-
played polyclonal B cell expansion, whereas older animals
usually developed clonal B cell lymphomas, which could be
propagated in immunodeficient (Rag2/gc/), but not WT
((C57BL/6xBALB/c) F1), animals (Figure 5C, Figure S4B, and
data not shown). The tumor cells (CD19+Fas+) were AA4.1,
CD138, CD43, CD21+, andCD23+ and thus resembledmature
follicular B cells (Figure 5D, Table S1, and data not shown). Of the
four tumors analyzed for surface immunoglobulins (Igs), one was
IgM+l+, one was IgM+k+, and the other two were IgG2+k+February 17, 2012 ª2012 Elsevier Inc. 741
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Figure 3. Disruption of Immune Surveillance Leads to Rapid, Fatal Lymphoproliferation in CD19-cre;LMP1flSTOP Mice
(A) Representative spleens of CD19-cre and CD19-cre;LMP1flSTOP mice repetitively treated with anti-CD4, -CD8, and -Thy1 antibodies (Abs) or PBS for
13–16 days.
(B) Numbers of CD19+Fas+ splenic B cells from mice as in (A). Each dot indicates one mouse.
(C) FACS analysis of splenocytes from indicated mice. In lower panels, analysis was on CD19+ cells.
(D) Immunoblotting of LMP1. Ctr B, CD43-depleted splenic B cells fromCD19-cremice; d3, day 3; four lanes from the right, splenic B cells from antibody-injected
CD19-cre;LMP1flSTOP mice; ns, nonspecific.
(E and F) Real-time RT-PCR (E) and immunoblotting (F) of AID in splenic B cells treated as indicated or isolated from antibody-injectedCD19-cre;LMP1flSTOPmice,
respectively. Ctr B, CD43-depleted splenic B cells fromC57BL/6mice; d3, day 3; the right lane in (F), splenic B cells from LMP1flSTOPmice cultured for 4 days after
TAT-Cre treatment.
See also Figure S3.(Figure 5E). Class switch recombination (CSR) in the latter
tumors may have been due to LMP1-induced AID expression
(He et al., 2003; Rastelli et al., 2008), which was indeed detect-
able in all LMP1+ lymphomas analyzed (Figure S4C). The rear-
ranged V region genes of these tumors, however, were not modi-
fied by somatic hypermutation (SHM; data not shown).
Immune Surveillance of LMP1-Driven Lymphomas
To address whether the immune surveillance of LMP1+ B cells
extends to the LMP1-driven lymphomas arising in the T cell-defi-
cient animals, we established clonal cell lines from several
LMP1+ tumors. In vitro killing assays with one such line revealed
efficient killing of the tumor cells by CD8+ T cells from CD19-742 Cell 148, 739–751, February 17, 2012 ª2012 Elsevier Inc.cre;LMP1flSTOP mice, whereas CD4+ T cells from the same
mice as well as activated ovalbumin-specific CD4+ or CD8+
T cells from OT-II (Barnden et al., 1998) or OT-I (Hogquist
et al., 1994) transgenic mice, respectively, had no effect (Figures
6A and 6B). However, when assayed for their capacity to
prevent tumor outgrowth in an in vivo cell transfer system, the
CD4+ T cells from CD19-cre;LMP1flSTOP mice efficiently sup-
pressed LMP1+ tumor growth, whereas the antitumor activity
of CD8+ T cells did not reach statistical significance (Figures
6C and 6D; CD4+ and CD8+ T cells from OT-II and OT-I mice
showed no effect in this assay). Nevertheless, both types of cells
eliminated nontransformed LMP1+ B cells upon transfer
(Figure S5A).
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Figure 4. TCRab T Cells Are Major Effectors in Controlling LMP1-Expressing B Cells, and TCRgd T Cells Also Contribute
(A) Spleens from 9-week-old CD19-cre;LMP1flSTOP mice of the indicated genotypes for TCRb and -d alleles. The lower panel shows the FACS analysis of the
corresponding splenic lymphocytes. CD19+Fas+ cells represent LMP1+ B cells.
(B) Numbers of CD19+Fas+ cells (LMP1+ B cells) in spleens of 8- to 11-week-old CD19-cre;LMP1flSTOP mice of the indicated genotypes for TCRb and -d alleles.
(C) Numbers of TCRgd+ cells in spleens of 8- to 11-week-old CD19-cre and CD19-cre;LMP1flSTOP mice of the indicated genotypes for TCRb and -d alleles.
(D) Survival of CD19-cre;LMP1flSTOP mice of the indicated genotypes for TCRb and -d alleles.
Bars in (B) and (C) show the respective median values.The superior efficiency of CD4+ T cells in tumor elimination
was unexpected. Their antitumor activity was not mediated by
IFNg and/or TNFa production, as it was completely preserved
in the presence of antibodies blocking these cytokines (see
Extended Experimental Procedures). There was also only
a minor increase of T cells secreting these cytokines upon cocul-
ture with tumor cells (Figure S5B). NKT cells, representing 10%–20% of the CD4+ T cells in the bone marrow preparations, could
not account for the antitumor activity of the CD4+ T cells
because elimination of these cells by FACS on the basis of
CD1d-tetramer staining had no effect (Figure 6D). We also
tested NKT cells purified from the bone marrow of CD19-
cre;LMP1flSTOP mice for antitumor activity in the cell transfer
system. Although limited by cell numbers, we were able toCell 148, 739–751, February 17, 2012 ª2012 Elsevier Inc. 743
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Figure 5. Clonal B Cell Lymphomas Arising in TCR-Deficient CD19-cre;LMP1flSTOP Mice
(A) H&E staining of spleen sections from a healthy control animal (left) and two terminally ill mice (middle and right) of the indicated genotypes. Six of nine animals
developed diffuse large B cell lymphoma (DLBCL) and three of nine plasmacytic tumors, as judged by their histological appearance. Scale bars in insets, 20 mm.
(B) Immunohistochemical staining of IRF4 on spleen sections from a control animal (left) and a TCR-deficientCD19-cre;LMP1flSTOP animal carrying a tumor (right).
Five of five tumors were IRF4 positive.
(C) Southern blot analysis of rearranged Ig VDJ and DJ gene segments in B cells from the indicated mice. The four lanes on the right depict mouse #1485, where
separate tumors developed in spleen (spl) and liver (Li). Tumors could be transplanted into immunodeficient recipients (Rag2/gc/) as exemplified for the
#1485 tumor in the liver. Dashed line, germline IgH configuration; wks, weeks.
(D and E) FACS analysis of four tumor lines. Data in (D) show representative analysis of one tumor line (966); Ctr B cells from the spleen of a (C57BL/6xBALB/c) F1
mouse.
See also Figure S4 and Table S1.transfer numbers of NKT cells corresponding to those in a pop-
ulation of CD4+ T cells that would control tumor growth. Though
at least some of the cells persisted in the transplanted animals
(Figure S5C), their antitumor activity was below the level of
significance (Figure 6D, right).744 Cell 148, 739–751, February 17, 2012 ª2012 Elsevier Inc.Similar to T cell recognition of EBV-infected B cells in humans
(Khanna and Burrows, 2000; Rickinson and Moss, 1997), the
CD4+ and CD8+ T cells from the bone marrow of CD19-
cre;LMP1flSTOP mice may recognize LMP1-expressing B cells
in an MHC-restricted manner. As shown in Figure 6E, these cells
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Figure 6. CD4+ and CD8+ T Cells Control LMP1+ Tumor Cells
(A) In vitro killing of LMP1+ tumor cells (line 966) by CD8+ T cells from CD19-cre;LMP1flSTOP mice, but not by CD4+ T cells from these mice or CD8+ and CD4+
T cells from OT-I and OT-II transgenic mice, respectively. E:T ratio, effector:target cell ratios.
(B) Representative active caspase-3 staining on the target cells (CD19+, tumor cells) is shown for a set of killing assays at an effector:target ratio of 60. Active
caspase-3 staining indicates apoptotic cells.
(C) Representative pictures showing tumor nodules in livers of Rag2/gc/ animals transplanted with 13 104 lymphoma cells (line 966) either alone or together
with 4 3 105 of the indicated T cells. Mice were analyzed on day 30 after transplantation. Scale bars, 10 mm.
(D) Summary of tumor nodule sizes in Rag2/gc/ animals transplanted with 1 3 104 lymphoma cells either alone or together with the indicated effectors at
various effector:tumor cell ratios. All effector cells were derived from CD19-cre;LMP1flSTOP mice except as indicated. Numbers (n) of animals for each group are
shown in the parentheses; CD4+ T-NKT, conventional CD4+ T cells. p values were calculated using Fisher’s exact test comparing the various groups to the ‘‘No
effectors’’ control or as indicated. Analysis of recipient mice on day 30 posttransfer revealed the absence of contaminating CD8+ cells in recipients of CD4+ cells
and vice versa (Figure S5C and data not shown).
(E) FACS analysis of the indicated antigens on CD19+ cells from the spleen of C57BL/6 mice (black line) and CD19+Fas+ (LMP1+) cells from the spleen of
TCRb/d/;CD19-cre;LMP1flSTOP mice (red line).
(F) Proliferation, monitored by CFSE dilution, of CD4+ and CD8+ T cells from CD19-cre;LMP1flSTOP mice cultured either alone or together with GFP- or LMP1-
expressing B cells from the indicated mice.
Data in (A) are representative of three independent experiments; (C and D) are from at least two experiments, except for the OT-II CD4+ and OT-I CD8+ T cells;
(E) are representative of two to five mice of each genotype; and (F) of two experiments.
See also Figure S5.
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express high levels of MHC I and II in conjunction with the cos-
timulatory and adhesion molecules CD80, CD86, and CD54
(ICAM-1). To address this issue, we performed coculture exper-
iments with activated B cells infected with an LMP1-encoding
retrovirus and lacking either MHC II or MHC I antigen expression.
Whereas both types of T cells proliferated in the presence of
LMP1-expressing (but not mock-infected) activated wild-type
B cells, the CD4+ T cells failed to respond to CIITA-deficient
B cells that lack MHC II antigen expression, and the CD8+
T cells showed severely impaired response to b2 microglobulin
(b2M) and thus MHC I-deficient B cells (Figure 6F). These results
suggest that both types of T cells recognize the LMP1-express-
ing B cell blasts and, by extension, the LMP1-driven lymphoma
cells by their TCR, through MHC-bound antigenic peptides. We
attempted to pinpoint LMP1-derived peptides involved in this
process by screening overlapping 20mers from every tenth
amino acid position of LMP1 in a CD4+ T cell proliferation assay
using activated B cell for presentation, but these attempts were
unsuccessful (see Extended Experimental Procedures).
Exploiting NKG2D for Immunotherapy
Extrapolating from the human (Hislop et al., 2007; Orange, 2006),
we speculated that the tumor cells may also be recognized by
NK cells (Vivier et al., 2008). Indeed, we found that, in spleen
and BM of CD19-cre;LMP1flSTOP mice, a fraction of the NK cells
were activated, and this activation encompassed the entire NK
cell population on a T cell-deficient background, where LMP1+
B cells gradually expand (Figure 7A). In addition, the stress
antigen Rae-1, a ligand of amajor NK-activating receptor termed
NKG2D (Diefenbach et al., 2001), was highly expressed on the
surface of the LMP1+ lymphoma cells (Figure 7B). This could
be due to AID expression as in Abelsonmurine leukemia virus-in-
fected B cells, allowing their recognition by NK cells (Gourzi
et al., 2006). Accordingly, NK cells from CD19-cre;LMP1flSTOP
mice were able to kill LMP1+ lymphoma cells in vitro, and killing
could be partially inhibited by an NKG2D-blocking antibody (Fig-
ure 7C). Recognition of CD95/Fas, abundantly expressed on the
tumor cells, also seemed to play a role in the killing reaction, as
killing was also partially inhibited by a Fas-Fc fusion protein.
Addition of both antibodies had an additive effect. Although
NK cells can thus recognize and attack LMP1+ B lymphoma
cells, they seem to play only a minor role in the in vivo surveil-
lance of these tumors, given that T cell-deficient CD19-
cre;LMP1flSTOP mice rapidly succumb to LMP1-driven
lymphomas. Further supporting and extending this notion is
our finding that CD19-cre;LMP1flSTOP mice on a NKG2D-defi-
cient background are perfectly protected against LMP1-driven
lymphomagenesis (Figure S6A). Thus, NKG2D receptors, which
are expressed not only on NK, but also several classes of acti-
vated T cells (Raulet, 2003), are not critical for tumor surveillance
in this system. Accordingly, like EBV-driven PTLD in the human
(see below), the LMP1+ lymphomas in the present mouse model
are not selected against NKG2D ligand expression, making them
ideal targets for NKG2D-based therapy. Following this
reasoning, we assessed whether these tumors can be targeted
by an NKG2D-Fc fusion protein, constructed by fusing the
NKG2D extracellular domain to an Fc fragment of mouse
IgG2a, which can activate killing by complement- and cell-medi-746 Cell 148, 739–751, February 17, 2012 ª2012 Elsevier Inc.ated cytotoxicity. Previous work showed that antibodies to MHC
class I chain-related protein A (MICA), a human NKG2D ligand,
stimulated killing of MICA-expressing tumor cells through
complement- and cell-dependent cytotoxicity (Jinushi et al.,
2006, 2008). Thus, a murine NKG2D-Fc fusion protein might
couple broad recognition of NKG2D ligand-expressing tumor
cells to Fc-mediated killing mechanisms. As shown by flow cy-
tometry, this protein readily bound to LMP1+ tumor cells (Fig-
ure 7D), and the cells were efficiently lysed upon incubation
with NKG2D-Fc and complement (Figure 7E). When tumor cells
were transferred into immunodeficient recipient mice, treatment
of the latter with moderate doses of NKG2D-Fc significantly
reduced tumor growth and prolonged the survival of the animals
(Figures 7F, 7G, and S6B–S6E). Although the NKG2D-Fc-treated
recipients eventually succumbed to tumor outgrowth, the tumor
cells continued to express Rae-1 at the same (high) levels as
those in animals treated with control antibody (data not shown).
Optimizing the dose of NKG2D-Fc and combining it with cyto-
kines such as granulocyte macrophage colony-stimulating
factor to promote antibody-dependent cell-mediated cytotox-
icity (Yu et al., 2010) will therefore be important considerations
in attempts to apply this therapeutic approach in the clinic. Sup-
porting the therapeutic potential of NKG2D-Fc fusion proteins in
human EBV-driven pathologies, we found that six of six human
EBV+ PTLDs examined expressed high levels of NKG2D ligands
(Figure 7H).
DISCUSSION
We demonstrate that expression of a single EBV protein, LMP1,
in B cells is sufficient to induce immune surveillance of the
LMP1+ cells by cells of the adaptive immune system and that
weakening of this surveillance mechanism results in the rapid
generation of LMP1-driven B cell lymphomas. Thus, this mouse
model recapitulates two salient features of EBV infection in
humans and offers itself for preclinical studies relating to the
pathogenesis and therapy of EBV-driven malignancies under
conditions of immunosuppression. In addition, the efficient
immune surveillance of LMP1-expressing B cells likely explains
the limited success of a previous attempt to induce B cell
lymphomas through an LMP1 transgene (Kulwichit et al., 1998).
EBV-driven lymphomas in immunosuppressed patients seem
typically to arise from post-GC B cells expressing somatically
mutated antibodies (Vakiani et al., 2008), as most of the virus
in latently infected individuals seems to reside in such cells
(Souza et al., 2005). In contrast, the present mouse model is
based on the transformation of newly generated B cells in
a setting inwhich, due to constitutive T cell deficiency, GCBcells
are not generated. Still, the tumors arising in the T cell-deficient
LMP1 transgenic mice are remarkably similar to EBV-driven
lymphomas in immunosuppressed patients. They are derived
from phenotypically mature B cells (CD19+, AA4.1, CD43,
CD21+, CD23+, and surface Ig+) and, in most cases, morpholog-
ically resemble human DLBCL, as is typical for monomorphic
PTLD (Harris et al., 2001). As do the latter tumors (Craig et al.,
2007; Vakiani et al., 2008) and consistent with active LMP1
signaling, they express the NF-kB target IRF4 (Saito et al.,
2007) and AID (He et al., 2003), the enzyme controlling CSR
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Figure 7. Reduced Tumor Growth in Transplanted Animals Receiving an NKG2D-Fc Fusion Protein
(A) Staining for the activation marker CD69 on NK cells (DX5+NK1.1+CD3) from the indicated mice.
(B) Staining of normal CD19+ B cells (Ctr B cells) from a TCRb+/–d/;CD19-cremouse and primary lymphoma cells from a T cell-deficient CD19-cre;LMP1flSTOP
mouse for expression of Rae-1.
(C) Killing of LMP1+ tumor cells (line 966) by NK cells fromCD19-cre;LMP1flSTOPmice in the presence of the indicated antibodies. NKG2D-blocking antibody, MI6;
Fas-Fc, Fas-ligand neutralizing fusion protein; rat IgG2a and human IgG1 served as controls for MI6 and Fas-Fc, respectively.
Data in (A) represent three mice of each genotype; (B) two primary lymphomas and three established lymphoma lines; (C) three experiments.
(D) Staining of the Ctr B cells and lymphoma cell lines for binding of mNKG2D-Fc fusion protein.
(E)Lysisof thesecellsupon incubationwith rabbit complementplusmNKG2D-Fc fusionproteinor isotypecontrol (mouse IgG2a) for2hr.Data indicatemeans±SEM.
(F) Spleens and livers from Rag2/gc/ animals transplanted with lymphoma cells (line 1485), repetitively treated with mNKG2D-Fc or isotype control, and
analyzed on day 33 after tumor transplantation.
(G) Survival of mice transplanted with lymphoma cells and treated as in (F). Each dot indicates one mouse.
Data in (D–G) are representative of three tumor lines tested.
(H) A representative human EBV+ PTLD sample stainedwith a hNKG2D-Fc fusion protein or isotype control mouse IgG2a. Six of six EBV+ PTLDswere stainedwith
similar results.
See also Figure S6.
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and SHM in normal B cell development. The expression of CSR-
dependent antibody isotypes by some of the tumors is another
feature shared by lymphomas arising in immunosuppressed
patients (Vakiani et al., 2008). Thus, although PTLD and AIDS-
associated B cell lymphoma express multiple EBV latency
genes, our results underscore a central pathogenic role for
LMP1 alone.
A striking result of the present work is the efficiency and tempo
of LMP1-induced B cell lymphomagenesis in the LMP1 trans-
genic, T cell-deficient animals. At 3months after birth, essentially
all such animals have died from aggressive, monoclonal B cell
tumors. This not only highlights the potential of LMP1 to trans-
form B cells in vivo, but also suggests that LMP1 expression
induces in the cells secondary oncogenic events, resulting in
the rapid outgrowth of monoclonal lymphomas. A candidate
pathway in this respect is the LMP1-induced expression of AID
(He et al., 2003), given the known oncogenic properties of AID
in terms of mediating chromosomal translocations and intro-
ducing point mutations into non-Ig loci (Pasqualucci et al.,
2001; Ramiro et al., 2004). A search for secondary oncogenic
events in the LMP1-induced tumors is ongoing and should be
directly relevant for the pathogenesis of EBV-driven lymphomas
in immunosuppressed patients.
The efficient immune surveillance of LMP1-expressing B cells
and of the resulting lymphomas resembles that of EBV-infected
B cells in the human and points to a major role of LMP1 in the
latter context. In both settings, TCRab cells are clearly the major
players, with the present data indicating no more than an ancil-
lary role for TCRgd cells. However, overall, our data do suggest
some participation of TCRgd cells, NKT, and activated NK cells
in the surveillance of the LMP1+ cells, a notion also supported
by the need for anti-Thy1 in addition to anti-CD4 and -CD8 anti-
bodies in the breaking of immune surveillance.
In vivo, activated CD4+ and CD8+ T cells appeared at the site
of generation of LMP1+ B cells, namely in the BM, and at least
some of these cells were able to specifically recognize the
LMP1+ B cells, as demonstrated by in vitro killing and in vivo
protection assays. For both classes of T cells, recognition of
the LMP1+ B cell blasts was MHC restricted and thus indicative
of TCR-based recognition of peptide-MHC complexes. The
nature of the peptides involved in this process is presently
a matter of speculation. Though our failure to pinpoint LMP1-
derived T cell epitopes does not exclude their existence, it is in
line with the absence of detectable immune surveillance of
mouse B cells expressing reciprocal LMP1-CD40 fusion proteins
(Ho¨mig-Ho¨lzel et al., 2008; Rastelli et al., 2008). The recognition
of the LMP1+ B cells could involve awide range of tumor-specific
and self-antigens that have been identified as T cell targets on
tumor cells (Boon et al., 2006). In human EBV-infected B cells,
these would include peptides from a variety of EBV proteins,
prominently the EBV nuclear antigens, with LMP1 peptides play-
ing a minor role, if any (Hislop et al., 2007). Though the recogni-
tion of EBV-infected and transformed B cells likely involves
a multitude of peptide-MHC complexes, the present results indi-
cate that LMP1 plays a crucial role in the induction of immune
surveillance. We suggest that this is due to the strong and
chronic activation of B cells by LMP1 through signaling path-
ways resembling those initiated by CD40 ligation. Like CD40-748 Cell 148, 739–751, February 17, 2012 ª2012 Elsevier Inc.activated B cells, B cells expressing LMP1 display high levels
of costimulatory and adhesion molecules on their surface, which
have been shown to critically enhance the immunogenicity of
humanB cell lymphomas through effective presentation of tumor
alloantigens to T cells (Schultze et al., 1995, 1997).
Surprisingly, in the in vivo tumor protection assays CD4+ cells
were superior to CD8+ cytotoxic cells despite their inability to kill
the tumor cells in vitro and functional independence of IFNg or
TNFa production. CD4+ T cells have been shown in another
context to exhibit antitumor activity in vivo by developing into
cytotoxic effectors (Quezada et al., 2010). Current immuno-
therapy of EBV-driven diseases in transplant recipients includes
infusion of EBV-specific cytotoxic T lymphocytes (CTLs) gener-
ated from autologous or donor-derived peripheral-blood mono-
nuclear cells (Gottschalk et al., 2005; Savoldo et al., 2006). In
most cases, these are predominantly CD8+ T cells, but some-
times CD4+ T cells predominate and seem to display similar
therapeutic efficacy. The present results draw attention to the
potential therapeutic value of EBV-specific CD4+ T cells in the
treatment of EBV-associated malignancies in the human.
A new aspect of the surveillance of LMP1 transformed B cells
emerging from the present work comes from the expression of
stress antigens on these cells, likely due to LMP1-induced AID
activity (Gourzi et al., 2006). These stress antigens, which we
found also highly expressed on human PTLDs, are recognized
by activating NK cell receptors, which are also expressed on
activated CD8+ and NKT cells (Raulet, 2003). Though NK cells
by themselves were unable to prevent LMP1-driven lymphoma-
genesis, we have developed a therapeutic approach for the
treatment of these tumors using the antigen binding domain of
the activating NK receptor NKG2D as a soluble protein, fused
to the Fc region of an antibody. We show in a proof-of-principle
experiment that injection of this fusion protein into recipients of
lymphoma cells strongly impedes the outgrowth of these highly
aggressive tumors in our preclinical mouse model. Future
studies will examine the relative contributions of complement-
dependent and phagocyte-mediated killing to the antitumor
effects. Because NKG2D ligands show limited expression in
healthy tissues, the NKG2D-Fc fusion protein might achieve
a favorable therapeutic index in PTLD patients. Indeed, high
titers of anti-MICA antibodies are associated with clinically
meaningful responses to cancer immunotherapy in the absence
of toxicity (Jinushi et al., 2006). Though our preclinical evaluation
of the NKG2D-Fc fusion protein focused on early tumors, reflect-
ing the rapid growth kinetics of the transplantable lines, future
clinical investigations should explore the optimal timing of
NKG2D-Fc administration and a potential integration with other
forms of lymphoma therapy. Finally, as NKG2D ligands are ex-
pressed by diverse hematologic and solid malignancies, the
NKG2D-Fc fusion protein might also prove applicable to other
clinical settings. Efforts to translate this therapeutic strategy to
testing in patients are underway.EXPERIMENTAL PROCEDURES
Mice and Depleting Antibody Treatment
To generate conditional LMP1 transgenic mice, the LMP1 coding sequence
derived from the EBV B95-8 strain, preceded by a loxP-flanked Neor-STOP
cassette, was cloned into the ubiquitously expressed Rosa26 locus (Sasaki
et al., 2006). Transgenic mice (LMP1flSTOP) were generated from BALB/c-
derived embryonic stem (ES) cells. In some experiments, a similar strain
recently generated from C57BL/6 ES cells was used, as indicated in the
text. Other mouse strains, all on the C57BL/6 background, include CD19-cre
mice; TCRb/, TCRd/, OT-II, OT-I, b2M/, and CIITA/ mice from the
Jackson Laboratory. lpr/lpr mice on the MRL/MpJ background were
purchased from the Jackson Laboratory and BALB/c mice from Taconic.
Some CIITA-deficient mice were kindly given to us by Dr. Arlene Sharpe and
NKG2D/ mice by Dr. David Raulet. Homozygous CD19-cre mice were
crossed with either BALB/c or LMP1flSTOP mice to generate CD19-cre or
CD19-cre;LMP1flSTOP mice on a (C57BL/6xBALB/c) F1 background. For anti-
body-mediated cell depletion, mice were injected intraperitoneally (i.p.) two
times with a 24 hr interval, followed by injections every 3–4 days with 600 mg
of the following depleting antibodies: anti-CD4 (YTS 191.1.2), anti-CD8 (YTS
169.4.2.1), and anti-Thy-1 (YTS 154.7.7.10), either alone or in combination.
All animals were maintained in specific pathogen-free conditions and handled
according to protocols approved by the Harvard University Institutional Animal
Care and Use Committee and by the Immune Disease Institute.
Tumor and Immune Cells Transfer
In one set of experiments, 1 3 104 tumor cells (line 966) were transferred (i.v.)
into Rag2/common g chain/ mice (Rag2/gc/, lacking B, T, and NK
cells) either alone or together with 4 3 105 TCRb+CD4+ or TCRb+CD8+ cells
(containing 50% activated, CD69+ cells) sorted from the BM of CD19-
cre;LMP1flSTOP or the spleen of OT-II and OT-I mice (all on the (C57BL/
6xBALB/c) F1 background). Recipients were analyzed on day 30 after trans-
plantation for tumor growth. In another set of experiments, Rag2/gc/
recipients were transplanted with the tumor cells either alone or together
with indicated numbers of TCRb+CD1dTetramerCD4+ (conventional CD4+ T)
or TCRb+CD1dTetramer+CD4+/– (NKT) cells sorted from the BM of CD19-
cre;LMP1flSTOP mice.
MHC Restriction
CD43 splenic B cells were purified from WT, CIITA/, or b2M/ C57BL/6
mice, activated by LPS at 20 mg/ml for 24 hr, and then infected with retrovi-
ruses, MSCV-IRES-GFP, or MSCV-LMP1-IRES-GFP (kind gifts of Drs. Ellen
Cahir-McFarland and Elliott Kieff). At 48 hr postinfection, 53 105 GFP+ B cells
were cocultured with 2.5 3 105 CFSE-labeled TCRb+CD4+ or TCRb+CD8+
cells sorted from the BM of CD19-cre;LMP1flSTOP mice (on a C57BL/6 back-
ground) in 96-well U-bottom plate with fresh medium added daily for 4 days.
The cells were stained with anti-TCRb, -CD4, -CD8, and -CD19 and analyzed
for CFSE levels.
NKG2D-Fc Fusion Proteins
Expression vectors were prepared with In-Fusion (Clontech) assembly, using
previously reported procedures and modular cassettes (Zhu et al., 2007).
Because NKG2D is a type II transmembrane protein, the DNA constructs
were composed of an optimized IL-2 signal sequence (Zhang et al., 2005),
the hinge-CH2-CH3 domains of mouse IgG2a beginning with EPKGP, an
IEGR linker, and the extracellular domain of either murine (amino acids
94–232; #AF054819) or human (amino acids 78–216) NKG2D (designated
mNKG2D-Fc and hNKG2D-Fc, respectively). Plasmids were electroporated
into Chinese hamster ovary DG44 cells, and stable clones were generated
with methotrexate selection. High producers were identified through assaying
culture supernatants for mIgG2a with an ELISA. Large-scale preparation of the
mNKG2D-Fc protein was performed commercially (Bio X Cell). The hNKG2D-
Fc protein was purified from conditioned supernatants with recombinant
protein G agarose (Invitrogen), according to the manufacturer’s protocols.
For FACS analysis, cells were stained with 10 mg/ml of mNKG2D-Fc or control
mIgG2a followed with a PE-conjugated goat anti-mouse IgG (Southern
Biotechnology). For complement-dependent lysis, tumor or control B cells
were suspended in cytotoxicity medium (RPMI plus 0.3% BSA) at 4 3
106 cells/ml and then incubated for 2 hr at 37C in varying concentrations of
mNKG2D-Fc or control mIgG2a and rabbit complement (Cedarlane Laborato-
ries) diluted with 7-AAD (BD Biosciences). After washing, the cells were
analyzed on a FACSCanto II. Specific lysis was calculated as: (7-AAD+% inexperimental well  7-AAD+% in complement only well)/(100  7-AAD+% in
complement only well). For in vivo treatment of transplanted tumors, tumor
cells (lines 815, 966, and 1485, all from T cell-deficient CD19-cre;LMP1flSTOP
mice) were transferred (i.v.; 13 105, 13 104, and 13 106 per mouse, respec-
tively) into Rag2/gc/ mice, and beginning 1 day later, recipients received
i.v. injections of 250 mg of mNKG2D-Fc or control mIgG2a every 2–3 days
seven times. The mice were monitored for tumor growth and analyzed when
terminally ill.
Statistical Analysis
Data were analyzed using unpaired two-tailed Student’s t test except where
indicated; a p value > 0.05 was considered not statistically significant (ns).
Survival curves were compared using the log rank test.
SUPPLEMENTAL INFORMATION
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